# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Patrick Donnelly maintains Revvity (NYSE:PKI) with a Buy and lowers the price target from $170 to $160.
Stifel analyst Daniel Arias maintains Revvity (NYSE:PKI) with a Hold and lowers the price target from $145 to $135.
Baird analyst Catherine Schulte maintains Revvity (NYSE:PKI) with a Outperform and lowers the price target from $182 to $165.
Barclays analyst Luke Sergott maintains Revvity (NYSE:PKI) with a Equal-Weight and lowers the price target from $140 to $125.
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. •...